+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029- Product Image
Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029- Product Image
New

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos, gRNA)), Application (Therapeutic, Research, Diagnostic), End User (Pharma, Biotech) - Global Forecast to 2029

  • PDF Icon

    Report

  • 255 Pages
  • January 2025
  • Region: Global
  • Markets and Markets
  • ID: 6044692
Description Jump to:
The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs. Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.

The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023

In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.

The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period

Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.

Asia Pacific: The fastest growing region in the oligonucleotide CDMO market

Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Supply Side - 65% and Demand Side - 35%
  • By Designation: (Managers) - 45%, (CXOs, Directors) - 30%, and (Executives) - 25%
  • By Region: North America - 40%, Europe - 25%, Asia-Pacific - 25%, Latin America - 5%, Middle East & Africa - 5%

List of Companies Profiled in the Report:

  • Bachem (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Agilent Technologies, Inc. (US)
  • Maravai Lifesciences (US)
  • GenScript (US)
  • Wuxi Apptec (China)
  • Eurofins Scientific (Luxembourg)
  • Lonza (Switzerland)
  • Danaher Corporation (US)
  • Syngene International Limited (US)
  • EUROAPI (France)
  • Ajinomoto Co., Inc. (Japan)
  • ST Pharm (South Korea)
  • Kaneka Corporation (Japan)
  • Aurigene Pharmaceutical Services Ltd. (India)
  • PolyPeptide Group (Switzerland)
  • Biospring (Germany)
  • Oligo factory (US)
  • Corden Pharma (Switzerland)
  • LGC Biosearch Technologies (UK)
  • Bio-Synthesis Inc (US)
  • Microsynth (Switzerland)
  • Synoligo Biotechnologies, Inc. (US)
  • Hongene Biotech Corporation (China)
  • Sylentis, S.A. (Spain)
  • Creative Biogene. (US)

Research Coverage:

This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
  • Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide CDMO market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered & Regions Considered
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.2 Primary Data
2.2 Market Estimation Methodology
2.2.1 Insights from Primary Experts
2.2.2 Top-Down Approach
2.3 Market Growth Rate Projections
2.4 Data Triangulation
2.5 Research Assumptions
2.6 Research Limitations
2.7 Risk Analysis
3 Executive Summary
4 Premium Insights
4.1 Oligonucleotide Cdmo Market Overview
4.2 North America: Oligonucleotide Cdmo Market, by Service Type & Country (2023)
4.3 Oligonucleotide Cdmo Market, by Type, 2024 vs 2029
4.4 Oligonucleotide Cdmo Market, by Application, 2024 vs 2029
4.5 Oligonucleotide Cdmo Market Share, by End-user, 2023
4.6 Oligonucleotide Cdmo Market: Geographic Growth Opportunities
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Focus on Development and Commercialization of Oligo-based Therapeutics
5.2.1.2 Advantages of Contract Development and Manufacturing
5.2.1.3 Increasing Focus on Precision/Personalized Medicine
5.2.1.4 Technological Advancements
5.2.2 Restraints
5.2.2.1 Complexities Associated with Therapeutic Oligonucleotide Manufacturing
5.2.3 Opportunities
5.2.3.1 Increasing Use of Oligos in Crispr-Cas9 Applications
5.2.4 Challenges
5.2.4.1 Lack of Sustainable and Eco-Friendly Supply Chain
5.3 Trends/Disruptions Impacting Customer Businesses
5.4 Supply Chain Analysis
5.5 Value Chain Analysis
5.6 Ecosystem Analysis
5.6.1 Role in Ecosystem
5.7 Technology Analysis
5.7.1 Key Technologies
5.7.1.1 Process Technologies
5.7.1.1.1 Solid-Phase Synthesis
5.7.1.1.2 Liquid-Phase Synthesis
5.7.1.1.3 Enzymatic Oligo Synthesis
5.7.2 Complementary Technologies
5.7.2.1 Purification, Analysis, and Quality Control Technologies
5.7.2.1.1 Chromatography
5.7.2.1.2 Mass Spectrometry
5.7.2.2 Other Technologies
5.7.2.2.1 Polymerase Chain Reaction (Pcr)
5.7.2.2.2 Next-Generation Sequencing
5.7.3 Adjacent Technologies
5.7.3.1 3D Printing
5.8 Pricing Analysis
5.8.1 Indicative Price of Oligonucleotide Cdmo Services, by Key Player
5.8.2 Average Selling Price, by Region (Qualitative)
5.9 Key Conferences & Events in 2024-2025
5.10 Regulatory Landscape
5.10.1 Regulatory Bodies, Government Agencies, and Other Organizations
5.10.2 Regulatory Framework
5.11 Porter's Five Forces Analysis
5.11.1 Degree of Competition
5.11.2 Bargaining Power of Suppliers
5.11.3 Bargaining Power of Buyers
5.11.4 Threat of Substitutes
5.11.5 Threat of New Entrants
5.12 Key Stakeholders & Buying Criteria
5.12.1 Influence of Stakeholders on Buying Process for Oligonucleotide Cdmo Services
5.13 Key Buying Criteria
5.14 Investment & Funding Scenario
5.15 Impact of AI/Gen AI on Oligonucleotide Cdmo Market
6 Oligonucleotide Cdmo Market, by Service Type
6.1 Introduction
6.2 Contract Manufacturing
6.2.1 Commercial Stage
6.2.1.1 Flexible, Scalable Production Facilities to Propel Market Growth
6.2.2 Clinical Stage
6.2.2.1 Growing Demand for Oligonucleotide-based Therapeutics to Drive Market
6.3 Contract Development
6.3.1 Growing Focus on Reducing Manufacturing Risks to Support Market Growth
6.4 Other Services
7 Oligonucleotide Cdmo Market, by Type
7.1 Introduction
7.2 Antisense Oligonucleotides
7.2.1 Specific Development & Manufacturing Requirements Well-Supported by Cdmos to Drive Market Growth
7.3 Small Interfering RNA
7.3.1 Potential in Therapeutic Applications to Drive Market Growth
7.4 Other Oligonucleotides
8 Oligonucleotide Cdmo Market, by Application
8.1 Introduction
8.2 Therapeutic Applications
8.2.1 Growing Demand for Oligonucleotide-based Therapeutics to Drive Market Growth
8.3 Research Applications
8.3.1 Use of Oligos in Sequencing for Advancing Drug Development to Support Growth
8.4 Diagnostic Applications
8.4.1 Growing Applications in Molecular Diagnostics and Ivd to Propel Market
9 Oligonucleotide Cdmo Market, by End-user
9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.2.1 Increased Investments in Oligonucleotide Drug Pipelines to Support Market Growth
9.3 Diagnostic Companies
9.3.1 Growth of Personalized Diagnostics to Propel Market
9.4 Other End-users
10 Oligonucleotide Cdmo Market, by Region
10.1 Introduction
10.2 North America
10.2.1 Macroeconomic Outlook for North America
10.2.2 US
10.2.2.1 Rising Approvals of Oligonucleotide-based Drugs to Support Market Growth
10.2.3 Canada
10.2.3.1 Government Initiatives to Drive Market Growth in Canada
10.3 Europe
10.3.1 Macroeconomic Outlook for Europe
10.3.2 Germany
10.3.2.1 Academic-Industry Collaborations to Drive Market
10.3.3 UK
10.3.3.1 Strategic Investments in Biomanufacturing to Boost Market Growth
10.3.4 France
10.3.4.1 Focus on Advanced Biologics Manufacturing to Drive Market
10.3.5 Italy
10.3.5.1 Increasing Focus on Biotechnology Innovation to Boost Market Growth
10.3.6 Spain
10.3.6.1 Strategic Investments in Biotechnology to Support Market Growth
10.3.7 Rest of Europe
10.4 Asia-Pacific
10.4.1 Macroeconomic Outlook for Asia-Pacific
10.4.2 China
10.4.2.1 Government-Backed Initiatives and Expansion of Major Companies to Strengthen Biotechnology Sector in China
10.4.3 Japan
10.4.3.1 Increased Investment in Oligonucleotide Research and Manufacturing to Boost Market
10.4.4 India
10.4.4.1 Rapidly Expanding Biopharma Ecosystem to Drive Market
10.4.5 South Korea
10.4.5.1 Robust Government Support to Expand Oligonucleotide Cdmo Sector
10.4.6 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Macroeconomic Outlook for Latin America
10.5.2 Brazil
10.5.2.1 Strong Research Institutions and Growing Collaboration Between Academia and Industry to Support Market Growth
10.5.3 Mexico
10.5.3.1 Rapidly Advancing Pharmaceutical and Biotechnology Sectors to Fuel Growth
10.5.4 Rest of Latin America
10.6 Middle East & Africa
10.6.1 Rising Investments in Healthcare and Growing Focus on Personalized Medicine to Drive Market
10.6.2 Macroeconomic Outlook for Middle East
10.6.3 Macroeconomic Outlook for Africa
11 Competitive Landscape
11.1 Overview
11.2 Key Player Strategies/Right to Win
11.2.1 Overview of Strategies Adopted by Players in Oligonucleotide Cdmo Market
11.3 Revenue Analysis, 2021-2023
11.4 Market Share Analysis, 2023
11.5 Company Evaluation Matrix: Key Players, 2023
11.5.1 Stars
11.5.2 Emerging Leaders
11.5.3 Pervasive Players
11.5.4 Participants
11.5.5 Company Footprint: Key Players, 2023
11.5.5.1 Company Footprint
11.5.5.2 Region Footprint
11.5.5.3 Service Type Footprint
11.5.5.4 Type Footprint
11.5.5.5 Application Footprint
11.6 Company Evaluation Matrix: Startups/SMEs, 2023
11.6.1 Progressive Companies
11.6.2 Responsive Companies
11.6.3 Dynamic Companies
11.6.4 Starting Blocks
11.6.5 Competitive Benchmarking
11.6.5.1 Detailed List of Key Startups/SMEs
11.6.5.2 Competitive Benchmarking of Startups/SMEs
11.7 Company Valuation and Financial Metrics
11.8 Brand/Service Comparison
11.9 Competitive Scenario
11.9.1 Deals
11.9.2 Expansions
12 Company Profiles
12.1 Key Players
12.1.1 Bachem
12.1.1.1 Business Overview
12.1.1.2 Services Offered
12.1.1.3 Recent Developments
12.1.1.3.1 Deals
12.1.1.4 Analyst's View
12.1.1.4.1 Key Strengths
12.1.1.4.2 Strategic Choices
12.1.1.4.3 Weaknesses and Competitive Threats
12.1.2 Thermo Fisher Scientific Inc.
12.1.2.1 Business Overview
12.1.2.2 Services Offered
12.1.2.3 Recent Developments
12.1.2.3.1 Deals
12.1.2.3.2 Expansions
12.1.2.4 Analyst's View
12.1.2.4.1 Key Strengths
12.1.2.4.2 Strategic Choices
12.1.2.4.3 Weaknesses and Competitive Threats
12.1.3 Agilent Technologies, Inc.
12.1.3.1 Business Overview
12.1.3.2 Services Offered
12.1.3.3 Recent Developments
12.1.3.3.1 Deals
12.1.3.3.2 Expansions
12.1.3.4 Analyst's View
12.1.3.4.1 Key Strengths
12.1.3.4.2 Strategic Choices
12.1.3.4.3 Weaknesses and Competitive Threats
12.1.4 Wuxi Apptec
12.1.4.1 Business Overview
12.1.4.2 Services Offered
12.1.4.3 Recent Developments
12.1.4.3.1 Expansions
12.1.4.4 Analyst's View
12.1.4.4.1 Key Strengths
12.1.4.4.2 Strategic Choices Made
12.1.4.4.3 Weaknesses and Competitive Threats
12.1.5 Maravai Lifesciences
12.1.5.1 Business Overview
12.1.5.2 Services Offered
12.1.5.3 Recent Developments
12.1.5.3.1 Deals
12.1.6 Lonza
12.1.6.1 Business Overview
12.1.6.2 Services Offered
12.1.6.3 Recent Developments
12.1.6.3.1 Deals
12.1.6.3.2 Expansions
12.1.7 Eurofins Scientific
12.1.7.1 Business Overview
12.1.7.2 Services Offered
12.1.7.3 Recent Developments
12.1.7.3.1 Deals
12.1.7.3.2 Expansions
12.1.8 Danaher Corporation
12.1.8.1 Business Overview
12.1.8.2 Services Offered
12.1.8.3 Recent Developments
12.1.8.3.1 Expansions
12.1.9 Genscript
12.1.9.1 Business Overview
12.1.9.2 Services Offered
12.1.9.3 Recent Developments
12.1.9.3.1 Expansions
12.1.10 Syngene International Limited
12.1.10.1 Business Overview
12.1.10.2 Services Offered
12.1.10.3 Recent Developments
12.1.10.3.1 Expansions
12.1.11 Euroapi
12.1.11.1 Business Overview
12.1.11.2 Services Offered
12.1.11.3 Recent Developments
12.1.11.3.1 Deals
12.1.11.3.2 Expansions
12.1.12 Ajinomoto Co. Inc.
12.1.12.1 Business Overview
12.1.12.2 Services Offered
12.1.13 St Pharm
12.1.13.1 Business Overview
12.1.13.2 Services Offered
12.1.13.3 Recent Developments
12.1.13.3.1 Expansions
12.1.13.3.2 Other Developments
12.1.14 Kaneka Corporation
12.1.14.1 Business Overview
12.1.14.2 Services Offered
12.1.15 Polypeptide Group
12.1.15.1 Business Overview
12.1.15.2 Services Offered
12.1.15.3 Recent Developments
12.1.15.3.1 Deals
12.1.16 Aurigene Pharmaceutical Services Ltd.
12.1.16.1 Business Overview
12.1.16.2 Services Offered
12.1.17 Biospring
12.1.17.1 Business Overview
12.1.17.2 Services Offered
12.1.17.3 Recent Developments
12.1.17.3.1 Service Approvals
12.1.17.3.2 Expansions
12.2 Other Players
12.2.1 Oligo Factory
12.2.2 Corden Pharma
12.2.3 Lgc Biosearch Technologies
12.2.4 Bi0-Synthesis, Inc.
12.2.5 Microsynth
12.2.6 Synoligo Biotechnologies, Inc.
12.2.7 Hongene Biotech Corporation
12.2.8 Sylentis, SA
12.2.9 Creative Biogene
13 Appendix
13.1 Discussion Guide
13.2 Knowledgestore: The Subscription Portal
13.3 Customization Options
List of Tables
Table 1 Impact Analysis of Supply-Side and Demand-Side Factors
Table 2 Oligonucleotide Cdmo Market: Risk Assessment Analysis
Table 3 Oligonucleotide Cdmo Market: Impact Analysis
Table 4 Fda-Approved Oligonucleotide-based Therapies (2016-2023)
Table 5 Indicative Price of Oligonucleotide Contract Manufacturing Services, by Key Player
Table 6 Oligonucleotide Cdmo Market: List of Conferences & Events
Table 7 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 8 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 9 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 10 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 11 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 12 Oligonucleotide Cdmo Market: Porter's Five Forces Analysis
Table 13 Influence of Stakeholders on Buying Process of Oligonucleotide Cdmo Services: Pharmaceutical & Biotechnology Companies
Table 14 Buying Criteria for Oligonucleotide Cdmo Market, by End-user
Table 15 Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 16 Oligonucleotide Contract Manufacturing Services Market, by Stage, 2022-2029 (USD Million)
Table 17 Oligonucleotide Contract Manufacturing Services Market, by Region, 2022-2029 (USD Million)
Table 18 North America: Oligonucleotide Contract Manufacturing Services Market, by Country, 2022-2029 (USD Million)
Table 19 Europe: Oligonucleotide Contract Manufacturing Services Market, by Country, 2022-2029 (USD Million)
Table 20 Asia-Pacific: Oligonucleotide Contract Manufacturing Services Market, by Country, 2022-2029 (USD Million)
Table 21 Latin America: Oligonucleotide Contract Manufacturing Services Market, by Country, 2022-2029 (USD Million)
Table 22 Commercial-Stage Oligonucleotide Contract Manufacturing Market, by Region, 2022-2029 (USD Million)
Table 23 North America: Commercial-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 24 Europe: Commercial-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 25 Asia-Pacific: Commercial-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 26 Latin America: Commercial-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 27 Clinical-Stage Oligonucleotide Contract Manufacturing Market, by Region, 2022-2029 (USD Million)
Table 28 North America: Clinical-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 29 Europe: Clinical-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 30 Asia-Pacific: Clinical-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 31 Latin America: Clinical-Stage Oligonucleotide Contract Manufacturing Market, by Country, 2022-2029 (USD Million)
Table 32 Oligonucleotide Contract Development Services Market, by Region, 2022-2029 (USD Million)
Table 33 North America: Oligonucleotide Contract Development Services Market, by Country, 2022-2029 (USD Million)
Table 34 Europe: Oligonucleotide Contract Development Services Market, by Country, 2022-2029 (USD Million)
Table 35 Asia-Pacific: Oligonucleotide Contract Development Services Market, by Country, 2022-2029 (USD Million)
Table 36 Latin America: Oligonucleotide Contract Development Services Market, by Country, 2022-2029 (USD Million)
Table 37 Other Oligonucleotide Cdmo Services Market, by Region, 2022-2029 (USD Million)
Table 38 North America: Other Oligonucleotide Cdmo Services Market, by Country, 2022-2029 (USD Million)
Table 39 Europe: Other Oligonucleotide Cdmo Services Market, by Country, 2022-2029 (USD Million)
Table 40 Asia-Pacific: Other Oligonucleotide Cdmo Services Market, by Country, 2022-2029 (USD Million)
Table 41 Latin America: Other Oligonucleotide Cdmo Services Market, by Country, 2022-2029 (USD Million)
Table 42 Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 43 Oligonucleotide Cdmo Market for Antisense Oligonucleotides, by Region, 2022-2029 (USD Million)
Table 44 North America: Oligonucleotide Cdmo Market for Antisense Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 45 Europe: Oligonucleotide Cdmo Market for Antisense Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 46 Asia-Pacific: Oligonucleotide Cdmo Market for Antisense Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 47 Latin America: Oligonucleotide Cdmo Market for Antisense Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 48 Oligonucleotide Cdmo Market for Sirna, by Region, 2022-2029 (USD Million)
Table 49 North America: Oligonucleotide Cdmo Market for Sirna, by Country, 2022-2029 (USD Million)
Table 50 Europe: Oligonucleotide Cdmo Market for Sirna, by Country, 2022-2029 (USD Million)
Table 51 Asia-Pacific: Oligonucleotide Cdmo Market for Sirna, by Country, 2022-2029 (USD Million)
Table 52 Latin America: Oligonucleotide Cdmo Market for Sirna, by Country, 2022-2029 (USD Million)
Table 53 Oligonucleotide Cdmo Market for Other Oligonucleotides, by Region, 2022-2029 (USD Million)
Table 54 North America: Oligonucleotide Cdmo Market for Other Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 55 Europe: Oligonucleotide Cdmo Market for Other Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 56 Asia-Pacific: Oligonucleotide Cdmo Market for Other Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 57 Latin America: Oligonucleotide Cdmo Market for Other Oligonucleotides, by Country, 2022-2029 (USD Million)
Table 58 Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 59 Oligonucleotide Cdmo Market for Therapeutic Applications, by Region, 2022-2029 (USD Million)
Table 60 North America: Oligonucleotide Cdmo Market for Therapeutic Applications, by Country, 2022-2029 (USD Million)
Table 61 Europe: Oligonucleotide Cdmo Market for Therapeutic Applications, by Country, 2022-2029 (USD Million)
Table 62 Asia-Pacific: Oligonucleotide Cdmo Market for Therapeutic Applications, by Country, 2022-2029 (USD Million)
Table 63 Latin America: Oligonucleotide Cdmo Market for Therapeutic Applications, by Country, 2022-2029 (USD Million)
Table 64 Oligonucleotide Cdmo Market for Research Applications, by Region, 2022-2029 (USD Million)
Table 65 North America: Oligonucleotide Cdmo Market for Research Applications, by Country, 2022-2029 (USD Million)
Table 66 Europe: Oligonucleotide Cdmo Market for Research Applications, by Country, 2022-2029 (USD Million)
Table 67 Asia-Pacific: Oligonucleotide Cdmo Market for Research Applications, by Country, 2022-2029 (USD Million)
Table 68 Latin America: Oligonucleotide Cdmo Market for Research Applications, by Country, 2022-2029 (USD Million)
Table 69 Oligonucleotide Cdmo Market for Diagnostic Applications, by Region, 2022-2029 (USD Million)
Table 70 North America: Oligonucleotide Cdmo Market for Diagnostic Applications, by Country, 2022-2029 (USD Million)
Table 71 Europe: Oligonucleotide Cdmo Market for Diagnostic Applications, by Country, 2022-2029 (USD Million)
Table 72 Asia-Pacific: Oligonucleotide Cdmo Market for Diagnostic Applications, by Country, 2022-2029 (USD Million)
Table 73 Latin America: Oligonucleotide Cdmo Market for Diagnostic Applications, by Country, 2022-2029 (USD Million)
Table 74 Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 75 Oligonucleotide Cdmo Market for Pharmaceutical & Biotechnology Companies, by Region, 2022-2029 (USD Million)
Table 76 North America: Oligonucleotide Cdmo Market for Pharmaceutical & Biotechnology Companies, by Country, 2022-2029 (USD Million)
Table 77 Europe: Oligonucleotide Cdmo Market for Pharmaceutical & Biotechnology Companies, by Country, 2022-2029 (USD Million)
Table 78 Asia-Pacific: Oligonucleotide Cdmo Market for Pharmaceutical & Biotechnology Companies, by Country, 2022-2029 (USD Million)
Table 79 Latin America: Oligonucleotide Cdmo Market for Pharmaceutical & Biotechnology Companies, by Country, 2022-2029 (USD Million)
Table 80 Oligonucleotide Cdmo Market for Diagnostic Companies, by Region, 2022-2029 (USD Million)
Table 81 North America: Oligonucleotide Cdmo Market for Diagnostic Companies, by Country, 2022-2029 (USD Million)
Table 82 Europe: Oligonucleotide Cdmo Market for Diagnostic Companies, by Country, 2022-2029 (USD Million)
Table 83 Asia-Pacific: Oligonucleotide Cdmo Market for Diagnostic Companies, by Country, 2022-2029 (USD Million)
Table 84 Latin America: Oligonucleotide Cdmo Market for Diagnostic Companies, by Country, 2022-2029 (USD Million)
Table 85 Oligonucleotide Cdmo Market for Other End-users, by Region, 2022-2029 (USD Million)
Table 86 North America: Oligonucleotide Cdmo Market for Other End-users, by Country, 2022-2029 (USD Million)
Table 87 Europe: Oligonucleotide Cdmo Market for Other End-users, by Country, 2022-2029 (USD Million)
Table 88 Asia-Pacific: Oligonucleotide Cdmo Market for Other End-users, by Country, 2022-2029 (USD Million)
Table 89 Latin America: Oligonucleotide Cdmo Market for Other End-users, by Country, 2022-2029 (USD Million)
Table 90 Oligonucleotide Cdmo Market, by Region, 2022-2029 (USD Million)
Table 91 North America: Key Macroindicators
Table 92 North America: Oligonucleotide Cdmo Market, by Country, 2022-2029 (USD Million)
Table 93 North America: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 94 North America: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 95 North America: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 96 North America: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 97 North America: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 98 US: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 99 US: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 100 US: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 101 US: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 102 US: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 103 Canada: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 104 Canada: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 105 Canada: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 106 Canada: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 107 Canada: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 108 Europe: Key Macroindicators
Table 109 Europe: Oligonucleotide Cdmo Market, by Country, 2022-2029 (USD Million)
Table 110 Europe: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 111 Europe: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 112 Europe: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 113 Europe: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 114 Europe: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 115 Germany: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 116 Germany: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 117 Germany: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 118 Germany: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 119 Germany: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 120 UK: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 121 UK: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 122 UK: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 123 UK: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 124 UK: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 125 France: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 126 France: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 127 France: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 128 France: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 129 France: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 130 Italy: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 131 Italy: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 132 Italy: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 133 Italy: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 134 Italy: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 135 Spain: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 136 Spain: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 137 Spain: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 138 Spain: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 139 Spain: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 140 Rest of Europe: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 141 Rest of Europe: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 142 Rest of Europe: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 143 Rest of Europe: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 144 Rest of Europe: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 145 Asia-Pacific: Key Macroindicators
Table 146 Asia-Pacific: Oligonucleotide Cdmo Market, by Country, 2022-2029 (USD Million)
Table 147 Asia-Pacific: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 148 Asia-Pacific: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 149 Asia-Pacific: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 150 Asia-Pacific: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 151 Asia-Pacific: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 152 China: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 153 China: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 154 China: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 155 China: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 156 China: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 157 Japan: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 158 Japan: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 159 Japan: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 160 Japan: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 161 Japan: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 162 India: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 163 India: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 164 India: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 165 India: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 166 India: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 167 South Korea: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 168 South Korea: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 169 South Korea: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 170 South Korea: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 171 South Korea: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 172 Rest of Asia-Pacific: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 173 Rest of Asia-Pacific: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 174 Rest of Asia-Pacific: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 175 Rest of Asia-Pacific: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 176 Rest of Asia-Pacific: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 177 Latin America: Key Macroindicators
Table 178 Latin America: Oligonucleotide Cdmo Market, by Country, 2022-2029 (USD Million)
Table 179 Latin America: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 180 Latin America: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 181 Latin America: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 182 Latin America: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 183 Latin America: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 184 Brazil: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 185 Brazil: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 186 Brazil: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 187 Brazil: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 188 Brazil: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 189 Mexico: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 190 Mexico: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 191 Mexico: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 192 Mexico: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 193 Mexico: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 194 Rest of Latin America: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 195 Rest of Latin America: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 196 Rest of Latin America: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 197 Rest of Latin America: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 198 Rest of Latin America: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 199 Middle East: Key Macroindicators
Table 200 Africa: Key Macroindicators
Table 201 Middle East & Africa: Oligonucleotide Cdmo Market, by Service Type, 2022-2029 (USD Million)
Table 202 Middle East & Africa: Oligonucleotide Contract Manufacturing Market, by Stage, 2022-2029 (USD Million)
Table 203 Middle East & Africa: Oligonucleotide Cdmo Market, by Application, 2022-2029 (USD Million)
Table 204 Middle East & Africa: Oligonucleotide Cdmo Market, by Type, 2022-2029 (USD Million)
Table 205 Middle East & Africa: Oligonucleotide Cdmo Market, by End-user, 2022-2029 (USD Million)
Table 206 Overview of Strategies Adopted by Key Players Deployed by Key Cdmos, January 2021-December 2024
Table 207 Oligonucleotide Cdmo Market: Degree of Competition
Table 208 Oligonucleotide Cdmo Market: Region Footprint
Table 209 Oligonucleotide Cdmo Market: Service Type Footprint
Table 210 Oligonucleotide Cdmo Market: Type Footprint
Table 211 Oligonucleotide Cdmo Market: Application Footprint
Table 212 Oligonucleotide Cdmo Market: Detailed List of Key Startup/SMEs
Table 213 Oligonucleotide Cdmo Market: Competitive Benchmarking of Key Startups/SMEs
Table 214 Oligonucleotide Cdmo Market: Deals, January 2021-November 2024
Table 215 Oligonucleotide Cdmo Market: Expansions, January 2021-November 2024
Table 216 Bachem: Company Overview
Table 217 Bachem: Services Offered
Table 218 Bachem: Deals, January 2021-December 2024
Table 219 Thermo Fisher Scientific: Company Overview
Table 220 Thermo Fisher Scientific: Services Offered
Table 221 Thermo Fisher Scientific: Deals, January 2021-December 2024
Table 222 Thermo Fisher Scientific: Expansions, January 2021-December 2024
Table 223 Agilent Technologies: Company Overview
Table 224 Agilent Technologies: Services Offered
Table 225 Agilent Technologies: Deals, January 2021-December 2024
Table 226 Agilent Technologies: Expansions, January 2021-December 2024
Table 227 Wuxi Apptec: Company Overview
Table 228 Wuxi Apptec: Services Offered
Table 229 Wuxi Apptec: Expansions, January 2021-December 2024
Table 230 Maravai Lifesciences: Company Overview
Table 231 Maravai Lifesciences: Services Offered
Table 232 Maravai Lifesciences: Deals, January 2021-December 2024
Table 233 Lonza: Company Overview
Table 234 Lonza: Services Offered
Table 235 Lonza: Deals, January 2021-December 2024
Table 236 Lonza: Expansions, January 2021-December 2024
Table 237 Eurofins Scientific: Company Overview
Table 238 Eurofins Scientific: Services Offered
Table 239 Eurofins Scientific: Deals, January 2021-December 2024
Table 240 Eurofins Scientific: Expansions, January 2021-December 2024
Table 241 Danaher Corporation: Company Overview
Table 242 Danaher Corporation: Services Offered
Table 243 Danaher Corporation: Expansions, January 2021-September 2024
Table 244 Genscript: Company Overview
Table 245 Genscript: Services Offered
Table 246 Genscript: Expansions, January 2021-December 2024
Table 247 Syngene International Limited: Company Overview
Table 248 Syngene International Limited: Services Offered
Table 249 Syngene International Limited: Expansions, January 2021-December 2024
Table 250 Euroapi: Company Overview
Table 251 Euroapi: Service Offered
Table 252 Euroapi: Deals, January 2021-December 2024
Table 253 Euroapi: Expansions, January 2021-December 2024
Table 254 Ajinomoto: Company Overview
Table 255 Ajinomoto: Services Offered
Table 256 St Pharm: Company Overview
Table 257 St Pharm: Services Offered
Table 258 St Pharm: Expansions, January 2021-December 2024
Table 259 St Pharm: Other Developments, January 2021-December 2024
Table 260 Kaneka Corporation: Company Overview
Table 261 Kaneka Corporation: Services Offered
Table 262 Polypeptide Group: Company Overview
Table 263 Polypeptide Group: Services Offered
Table 264 Polypeptide Group: Deals, January 2021-December 2024
Table 265 Aurigene Pharmaceutical Services: Company Overview
Table 266 Aurigene Pharmaceutical Services: Services Offered
Table 267 Biospring: Company Overview
Table 268 Biospring: Services Offered
Table 269 Biospring: Service Approvals, January 2021-December 2024
Table 270 Biospring: Expansions, January 2021-December 2024
List of Figures
Figure 1 Oligonucleotide Cdmo Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primaries: Oligonucleotide Cdmo Market
Figure 4 Market Size Estimation: Supply-Side Analysis, 2023
Figure 5 Market Size Estimation: Approach 1 (Revenue Share Analysis), 2023
Figure 6 Illustrative Example of Bachem: Revenue Share Analysis, 2023
Figure 7 Market Size Validation from Primary Sources
Figure 8 Market Size Estimation Methodology: Top-Down Approach
Figure 9 Oligonucleotide Cdmo Market: CAGR Projections
Figure 10 Data Triangulation Methodology
Figure 11 Oligonucleotide Cdmo Market, by Service Type, 2024 vs. 2029 (USD Million)
Figure 12 Oligonucleotide Contract Manufacturing Market, by Stage, 2024 vs. 2029 (USD Million)
Figure 13 Oligonucleotide Cdmo Market, by Type, 2024 vs. 2029 (USD Million)
Figure 14 Oligonucleotide Cdmo Market, by Application, 2024 vs. 2029 (USD Million)
Figure 15 Oligonucleotide Cdmo Market, by End-user, 2024 vs. 2029 (USD Million)
Figure 16 Oligonucleotide Cdmo Market: Geographic Snapshot
Figure 17 Growing Focus on Development and Commercialization of Oligo-based Therapeutics - a Key Factor Driving Growth
Figure 18 Contract Manufacturing Accounted for Largest Share of North American Oligonucleotide Cdmo Market in 2023
Figure 19 Antisense Oligonucleotides Segment to Dominate Market Till 2029
Figure 20 Therapeutic Applications to Hold Largest Market Share Throughout Forecast Period
Figure 21 Pharmaceutical & Biotechnology Companies Held Largest Share of End-user Market in 2023
Figure 22 China to Register Highest Growth During Forecast Period
Figure 23 Oligonucleotide Cdmo Market: Drivers, Restraints, Opportunities, and Challenges
Figure 24 Revenue Shift and New Revenue Pockets for Oligonucleotide Cdmos
Figure 25 Supply Chain Analysis: Direct Distribution Strategy Preferred by Prominent Companies
Figure 26 Value Chain Analysis - Maximum Value Added During Manufacturing Phase
Figure 27 Oligonucleotide Cdmo Services Market Ecosystem
Figure 28 Oligonucleotide Cdmo Market: Porter's Five Forces Analysis
Figure 29 Influence of Stakeholders on Buying Process of Cdmo Services (Pharmaceutical & Biotechnology Companies)
Figure 30 Buying Criteria of End-users
Figure 31 Impact of AI/Gen AI on Oligonucleotide Cdmo Market
Figure 32 North America: Oligonucleotide Cdmo Market Snapshot
Figure 33 Asia-Pacific: Oligonucleotide Cdmo Market Snapshot
Figure 34 Oligonucleotide Cdmo Market: Revenue Analysis of Key Players, 2021-2023 (USD Million)
Figure 35 Oligonucleotide Cdmo Market Share Analysis of Key Players, 2023
Figure 36 Oligonucleotide Cdmo Market: Company Evaluation Matrix (Key Players), 2023
Figure 37 Oligonucleotide Cdmo Market: Company Footprint
Figure 38 Oligonucleotide Cdmo Market: Company Evaluation Matrix (Startups/SMEs), 2023
Figure 39 Oligonucleotide Cdmo Market: Year-To-Date (Ytd) Price Total Return and 5-Year Stock Beta of Key Vendors, 2024
Figure 40 Oligonucleotide Cdmo Market: EV/EBITDA of Key Vendors, 2024
Figure 41 Oligonucleotide Cdmo Market: Brand/Service Comparison Matrix
Figure 42 Bachem: Company Snapshot (2023)
Figure 43 Thermo Fisher Scientific: Company Snapshot (2023)
Figure 44 Agilent Technologies: Company Snapshot (2023)
Figure 45 Wuxi Apptec: Company Snapshot (2023)
Figure 46 Maravai Lifesciences: Company Snapshot (2023)
Figure 47 Lonza: Company Snapshot (2023)
Figure 48 Eurofins Scientific: Company Snapshot (2023)
Figure 49 Danaher Corporation: Company Snapshot (2023)
Figure 50 Genscript: Company Snapshot (2023)
Figure 51 Syngene International Limited: Company Snapshot (2023)
Figure 52 Euroapi: Company Snapshot (2023)
Figure 53 Ajinomoto: Company Snapshot (2023)
Figure 54 St Pharm: Company Snapshot (2023)
Figure 55 Kaneka Corporation: Company Snapshot (2023)
Figure 56 Polypeptide Group: Company Snapshot (2023)

Companies Mentioned

  • Bachem
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Wuxi Apptec
  • Maravai Lifesciences
  • Lonza
  • Eurofins Scientific
  • Danaher Corporation
  • Genscript
  • Syngene International Limited
  • Euroapi
  • Ajinomoto Co. Inc.
  • St Pharm
  • Kaneka Corporation
  • Polypeptide Group
  • Aurigene Pharmaceutical Services Ltd.
  • Biospring
  • Oligo Factory
  • Corden Pharma
  • Lgc Biosearch Technologies
  • Bi0-Synthesis, Inc.
  • Microsynth
  • Synoligo Biotechnologies, Inc.
  • Hongene Biotech Corporation
  • Sylentis, SA
  • Creative Biogene

Table Information

Report AttributeDetails
No. of Pages255
PublishedJanuary 2025
Forecast Period2024 - 2029
Estimated Market Value ( USD ) in 2024 $ 2.51 Billion
Forecasted Market Value ( USD ) by 2029 $ 6.73 Billion
Compound Annual Growth Rate21.8%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market by Product, by Service Type, by End-User, and By Region - Product Image

Peptide and Oligonucleotide CDMO Market by Product, by Service Type, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
Peptide And Oligonucleotide CDMO Global Market Report 2024 - Product Image

Peptide And Oligonucleotide CDMO Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, End User, and Region - Analysis and Forecast, 2023-2033 - Product Image

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis Method, Product, Technology, End User, and Region - Analysis and Forecast, 2023-2033

  • Report
  • 206 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.